Does anyone know of a recent update with respect to Biglycan and how far along it is to get into trials?
It is my understanding that Utrophin (as being developed by Summit) by itself cannot help with nNOS localization. This could mean that there may not be adequate blood flow for healthy muscle activity even with Utrophin substituting for Dystrophin. Biglycan is supposed to recruit both Utrophin and nNOS (in addition to other proteins in the sarcolemma). However, the last article I can see is from 2012. Even the latest news on Tivorsan's site is from 2012.
I emailed Dr. Justin Fallon earlier this year about trials with TVN-102, he said they would not start until 2015. He gave no time frame in 2015, just that they are at least a year away.